ArticleFrontiers in endocrinology2025
Mitoxantrone hydrochloride injection guided sentinel lymph node biopsy in cN0 BRAF V600E-mutated papillary thyroid carcinoma: a feasibility study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The BRAF V600E mutation in papillary thyroid carcinoma (PTC) is linked to aggressive behavior and frequent occult central lymph node metastases (CLNM), posing a surgical dilemma in clinically node-negative (cN0) patients. Sentinel lymph node biopsy (SLNB) could enable selective intervention, but its accuracy depends on tracer performance. We investigated the utility of SLNB using mitoxantrone hydrochloride injection (MHI) as a novel lymphatic tracer to determine its feasibility and diagnostic performance for occult metastases in patients with cN0, BRAF V600E-mutated, unilateral PTC. Methods: 48 patients with cN0, BRAF V600E-mutated unilateral PTC underwent intraoperative SLNB using MHI, followed by ipsilateral lobectomy with isthmusectomy and prophylactic central neck dissection (PCND). The diagnostic accuracy of SLNB was evaluated by comparing its results with the final histological results from PCND serving as the gold standard. Short-term postoperative complications were recorded to assess the safety of the procedure. Results: Sentinel lymph nodes (SLNs) were identified in 46 out of 48 patients (95.8%), with 62 SLNs retrieved, most commonly in the peritracheal region (93.5%). Intraoperative frozen section analysis identified 21 patients with positive SLNs and 25 with negative SLNs. Final pathology confirmed CLNM in 23 patients (47.9%). The sensitivity, specificity, negative predictive value (NPV), and positive predictive value (PPV) of SLNB for detecting CLNM were 91.3%, 100%, 92.6%, and 100%, respectively. Postoperatively, two patients (4.2%) experienced transient vocal cord palsy, with complete resolution within one week. No cases of parathyroid injury or removal were observed, and there were no instances of transient hypoparathyroidism or permanent complications. Conclusion: In patients with cN0, BRAF V600E-mutated PTC, SLNB using mitoxantrone hydrochloride injection is technically feasible and demonstrates high sensitivity and specificity. This approach may help identify individuals with occult central compartment metastases, thereby potentially avoiding unnecessary PCND in those with negative SLNs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.